Brit J Heamatol: Hydroxyurea exposure in women with sickle cell disease with ovarian reserve.

!---- For women with sickle cell disease (SCD), the use of modern ovarian reserve measures may help resolve the question of whether SCD or hydroxyurea (HC) affects female reproductive life.anti-miaole tube hormone (AMH) is a known marker of ovarian reserve and can be used to evaluate ovarian follicle reserve function., researchers used a standard clinical test to measure AMH in 285 samples of 93 female hemoglobin SS subjects from the Hydroxyreado Center Study (MSH), which was approved by the U.S. Food and Drug Administration for adult treatment of HCSCD, in a study published in the journal British Journal of Haematology.there were no samples of MSH random parts, so samples from the 10-year-old MSH follow-up study were analyzed. most subjectshad been exposed to HC (86/93).the median AMH level of the subjects was lower than the age and gender matching reference values.the median level of AMH was consistent with reduced ovarian reserve (a risk factor for infertility), which occurred in subjects aged 25-30.in healthy women, this happens after the age of 40.in multivariate analysis, the use of HC is independently related to low AMH (beta-0.001, 95% confidence interval is -0.002 to 0.000; P-0.006).these results showed that hemoglobin SS had premature decreased ovarian reserve function, and HC increased the likelihood of this outcome..